Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria
The monoclonal anti‐immunoglobulin E (IgE) antibody, omalizumab, was the first drug approved for use in patients with chronic idiopathic/spontaneous urticaria…
onlinelibrary.wiley.com